194 related articles for article (PubMed ID: 36569876)
21. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
22. [Risk factors of postoperative complication after total gastrectomy in advanced gastric cancer patients receiving neoadjuvant chemotherapy].
Cui H; Zhang KC; Cao B; Deng H; Liu GX; Cui JX; Xie TY; Liang WQ; Zhang QP; Wang N; Chen L; Wei B
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):153-159. PubMed ID: 33508921
[No Abstract] [Full Text] [Related]
23. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
24. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Front Immunol; 2022; 13():986359. PubMed ID: 36059550
[TBL] [Abstract][Full Text] [Related]
25. Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis.
Matsui R; Inaki N; Tsuji T
Clin Nutr; 2021 May; 40(5):2745-2753. PubMed ID: 33933740
[TBL] [Abstract][Full Text] [Related]
26. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
27. Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
Jang MK; Park S; Park C; Doorenbos AZ; Go J; Kim S
Breast; 2022 Dec; 66():1-7. PubMed ID: 36063619
[TBL] [Abstract][Full Text] [Related]
28. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
[TBL] [Abstract][Full Text] [Related]
29. Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer.
Palmela C; Velho S; Agostinho L; Branco F; Santos M; Santos MP; Oliveira MH; Strecht J; Maio R; Cravo M; Baracos VE
J Gastric Cancer; 2017 Mar; 17(1):74-87. PubMed ID: 28337365
[TBL] [Abstract][Full Text] [Related]
30.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
31. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
[TBL] [Abstract][Full Text] [Related]
32. Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors.
Faron A; Opheys NS; Nowak S; Sprinkart AM; Isaak A; Theis M; Mesropyan N; Endler C; Sirokay J; Pieper CC; Kuetting D; Attenberger U; Landsberg J; Luetkens JA
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943551
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer.
Sakin A; Sahin S; Sakin A; Aldemir MN; Bayram I; Kotan C
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2723-2731. PubMed ID: 32986374
[TBL] [Abstract][Full Text] [Related]
34. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
Ang J; Hu L; Huang PT; Wu JX; Huang LN; Cao CH; Zheng YX; Chen L
World J Gastroenterol; 2012 Dec; 18(47):7026-32. PubMed ID: 23323004
[TBL] [Abstract][Full Text] [Related]
35. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
[TBL] [Abstract][Full Text] [Related]
36. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
37. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
[TBL] [Abstract][Full Text] [Related]
38. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
[TBL] [Abstract][Full Text] [Related]
39. Impact of visceral adipose tissue on long-term outcomes after gastrectomy for advanced gastric cancer.
Matsui R; Inaki N; Tsuji T
Nutrition; 2022 May; 97():111619. PubMed ID: 35231854
[TBL] [Abstract][Full Text] [Related]
40. Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.
Xu J; Wu Y; Xu Y; Qiu Y; Li X; Song Y; Zhang L
Front Immunol; 2022; 13():802672. PubMed ID: 35173721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
